The sites that hit enrollment targets on your last oncology trial are probably the wrong pick for your next rare disease study. And the feasibility questionnaire you sent them will not tell you that.
Clinical trial site selection is treated as an operational problem: check the boxes on investigator qualifications, patient access, and infrastructure, then activate the sites you have used before. But the data tells a different story. Tufts CSDD research found that 37% of investigative sites under-enroll and 11% fail to enroll a single patient. Phesi's analysis of 173 cancer trials found that 19% of sites enrolled only one patient and together contributed under 3% of patients, which drags down enrollment rates and dilutes resources from the sites actually performing. The industry responds by over-selecting sites, which drives up costs further.
The real issue is not site capability. It is the disconnect between what sponsors know about a site's past performance and what actually predicts success on a specific protocol. And for CROs, sites, and service providers trying to win more studies, understanding that disconnect is the difference between getting selected and getting ignored.
TL;DR: Site selection fails because sponsors rely on familiarity and static feasibility data. Performance is protocol-specific, not transferable. Teams that combine predictive analytics (where are the patients?) with signal intelligence (when are sponsors making decisions?) win more studies and build lasting partnerships. The organizations that connect their feasibility data to commercial intelligence have a structural advantage over those that treat them as separate functions.
Your Best Sites Last Year Are Often the Wrong Pick for This Trial
This is the uncomfortable truth that most clinical operations teams avoid confronting: site performance does not transfer reliably across protocols.
A Circulation: Heart Failure analysis of the ASCEND-HF trial looked at 7,141 patients across 398 sites enrolled under one protocol. Patients at high-enrolling sites had different clinical profiles, completed the protocol more often and had different 30-day outcomes from patients at low-enrolling sites, and the effect varied by region.
In practical terms, a site that enrolled well in a Phase 3 cardiovascular trial might enroll no one in a Phase 2 rare disease study. The PI's therapeutic familiarity changes. The patient catchment area may not overlap with the new indication. The site's experience with specific biomarkers, endpoints, or measurement techniques (increasingly important in precision medicine) may not exist.
Yet sponsors keep defaulting to known networks: they are casting the same net in the same water. Meanwhile investigators leave research and new ones arrive, so the pool itself keeps shifting underneath static selection models.
The contrarian position here is simple: stop treating past enrollment numbers as predictive of future performance. They are descriptive of a different protocol, a different patient population, and often a different competitive landscape for recruitment. What actually predicts success is protocol-specific fit, and assessing that requires intelligence that most feasibility processes never capture.
The Disconnect Between Feasibility Data and Commercial Intelligence
Most CROs and sponsor organizations run two completely separate systems. On the clinical operations side, there is feasibility data: investigator databases, historical enrollment metrics, site qualification visit reports. On the commercial side, there is business development intelligence: which sponsors are funding new programs, which CROs are winning mandates, where the RFPs are flowing.
These systems almost never talk to each other.
The consequence is that commercial teams prospect sponsors without understanding the operational realities of site performance, while clinical operations teams select sites without visibility into the competitive landscape for investigator attention. A site might look perfect on paper, but if that PI is already committed to three competing trials in the same therapeutic area, your enrollment projections are fiction.
This is where account intelligence changes the equation. When you connect sponsor pipeline data, clinical trial registry signals, and commercial relationship intelligence into one view, you can answer questions that neither system addresses alone:
- Which sponsors are actively planning new studies in therapeutic areas where your sites have genuine patient access?
- Which of your investigators are overcommitted, and which have capacity that aligns with upcoming protocols?
- Where are enrollment delays creating rescue opportunities, and can you respond before the sponsor's preferred network fills the gap?
The organizations that connect these systems have a structural advantage. They prospect the right sponsors at the right time, position the right sites for the right protocols, and build a feedback loop between commercial wins and operational performance.
“The AI templates were a surprise delight. We expected the data, but the pre-built email suggestions turned out to be much better than expected and a huge help, especially for newer reps.”
Sabina Malochleb-Bazaud
Senior Sales Operations Administrator, Cytel
What a Signal-to-Selection Sequence Actually Looks Like
Frameworks are useful. Seeing one in action is better. Here is an illustrative walkthrough built from patterns we see across life sciences commercial teams. The company, dates and numbers are invented.
Week 1: The signal fires. A mid-size biotech publishes positive Phase 2 interim results for a NASH therapy. The data appears in a press release on January 15, and the company says it plans a Phase 3 with sites across North America and Europe.
Week 1-2: Research and alignment. The CRO's business development team pulls the sponsor's pipeline, identifies the VP of Clinical Operations from recent conference presentations, and reviews the sponsor's past trials in metabolic disease. They find that the Phase 2 had enrollment challenges in two geographies, with three sites producing zero patients. They also note the sponsor recently hired a new Head of Site Management, a signal that site network decisions are actively being reassessed.
Week 2: Signal-driven outreach. The BD lead sends a short email referencing the positive Phase 2 results, congratulating the team, and noting that their CRO has site networks with strong hepatology and endocrinology referral relationships in the geographies where Phase 2 under-enrolled. The email proposes a 20-minute call to discuss feasibility alignment, not a generic capabilities presentation.
Week 3: The conversation. The sponsor responds. The call focuses on specific enrollment challenges from Phase 2 and how the CRO's site network addresses them. The CRO shares anonymized enrollment data from comparable protocols, not just general capabilities.
Week 6: Shortlisted. The CRO is included in the RFP for Phase 3 site management. They entered the process two months before the RFP was published because they acted on the signal when it appeared.
This is the difference between reactive prospecting (waiting for the RFP) and proactive intelligence (engaging during the decision window). The same logic is set out in how to find clinical trial sponsors before they pick a CRO. For a deeper look at these buying signals in practice, see our guide to signal-based prospecting in life sciences.
Where Predictive Analytics Falls Short (and What Fills the Gap)
The industry is investing heavily in predictive site selection, and for good reason. Sponsors and CROs now rank sites by expected recruitment using EHR data, claims data, and geo-demographic modeling rather than questionnaires alone.
These tools answer a critical question: where are the patients? EHR-based feasibility can model real patient counts, comorbidities, medication patterns, and visit frequency with far more accuracy than a feasibility questionnaire filled out by an optimistic site coordinator. Geo-demographic modeling also helps sponsors prepare for FDA's Diversity Action Plan requirement by identifying sites with access to underrepresented populations.
But predictive analytics has a blind spot. It tells you where patients are. It does not tell you when sponsors need them.
A site might have the ideal patient population for a rare disease protocol, but if no sponsor is actively planning a trial in that indication, the intelligence is inert. Conversely, when a sponsor posts positive Phase 2 results and begins site selection for Phase 3, the window to engage is short. Predictive patient data without commercial timing intelligence is a catalog without a buyer.
The teams winning the most studies combine both: predictive analytics to identify protocol-specific site fit, and signal intelligence to engage sponsors during the decision window. Neither is sufficient alone.
“All of the vendors that I've worked with, all of the onboarding that I have had to deal with, I will say, hands down, Salesmotion was the easiest that I have had.”
Lyndsay Thomson
Head of Sales Operations, Cytel
The Sponsor Side: Managing Site Networks with Intelligence
This article would be incomplete if it only addressed how to sell to sponsors. The same intelligence framework applies to sponsor-side teams and large CROs managing existing site networks.
For a large CRO such as Parexel or IQVIA, the challenge is not finding sites. It is managing a network of thousands of sites across geographies and therapeutic areas, and knowing which sites to activate for a specific protocol. Historical performance data helps, but as discussed above, past performance is protocol-specific.
Sponsor-side teams are increasingly using real-time intelligence to:
- Monitor investigator availability and competing commitments. If a high-performing PI just committed to two competing trials, activating that site for your study is a predictable enrollment failure.
- Track regulatory and compliance signals. FDA warning letters, inspection findings, and IRB issues at sites in your network represent risks that static databases do not capture.
- Identify emerging sites before they appear in industry databases. New research programs at academic medical centers, recently credentialed PIs, and sites expanding into new therapeutic areas represent untapped capacity.
The common thread is the same: static data (feasibility questionnaires, investigator databases) provides a snapshot. Intelligence (signals, competitive monitoring, real-time tracking) provides a motion picture. The organizations making the best site selection decisions are watching the motion picture.
What Happens When You Connect the Systems
When Cytel, a global leader in advanced analytics for life sciences, evaluated their commercial workflow, the problem was structural. Their team toggled across five or more disconnected tools to prepare for sponsor conversations, and reps spent hours on manual account research before they could even assess whether an opportunity was worth pursuing.
The numbers after consolidating into a single intelligence platform:
- Research time cut by 50% across the sales team
- Account planning 30% faster
- 6 hours saved per rep per week
- Five disconnected tools replaced by one, so every team member works from the same intelligence
- Faster ramp for new hires, because AI-generated messaging templates double as a learning tool for understanding accounts, therapeutic areas, and sponsor priorities
Jillian Cormier, VP of Business Development at Cytel, described the shift: for newer reps, the platform functions as both a research tool and a learning tool, helping them understand the account, the context, and how to message effectively without needing weeks of training.
The operational impact is measurable. At Cytel's 6 hours saved per rep per week, a team of ten reps gets back about 60 hours a week, and those hours go into sponsor conversations, not database browsing. The CRO business development page shows the setup.
Key Takeaways
- Past site performance does not reliably predict future enrollment. Performance is protocol-specific. Stop treating historical enrollment numbers as the primary selection criterion.
- Most organizations waste their feasibility data by never connecting it to commercial intelligence. Bridging clinical operations data with business development signals creates a structural advantage.
- Predictive analytics tells you where patients are. Signal intelligence tells you when sponsors need them. You need both, and neither is sufficient alone.
- Trigger-based outreach works because of timing. The difference is acting during the decision window, not after it closes.
- FDA's Diversity Action Plan requirement is reshaping site selection planning. Geo-demographic modeling helps sites show diverse patient access.
- Consolidating intelligence into one system delivers measurable results. Cytel cut research time by 50% and made account planning 30% faster across their commercial team.
Frequently Asked Questions
Why do so many clinical trial sites fail to enroll patients?
Site enrollment failure is protocol-specific, not a reflection of general site capability. A site that performs well in one therapeutic area may lack the patient population, investigator expertise, or endpoint measurement experience for a different protocol. According to Tufts CSDD research, 37% of sites under-enroll and 11% fail to enroll a single patient. The root causes include overly optimistic feasibility assessments, investigator overcommitment to competing trials, and a disconnect between sponsor site selection criteria and actual protocol requirements.
How are FDA diversity requirements changing clinical trial site selection?
FDORA requires sponsors of Phase 3 and other pivotal studies to submit Diversity Action Plans with enrollment goals by race, ethnicity, sex, and age group. The requirement takes effect after FDA finalizes its guidance; when we checked in October 2026, FDA's guidance was still the June 2024 draft. Sponsors preparing for it account for the demographic composition of a site's patient population, not just its enrollment history. Sponsors are using geo-demographic modeling and EHR data to identify sites with access to underrepresented populations, and sites that can demonstrate diverse patient access have a growing competitive advantage.
What is the difference between predictive site selection and signal-based prospecting?
Predictive site selection uses historical data, EHR records, and machine learning to estimate which sites are most likely to enroll patients for a specific protocol. It answers "where are the patients?" Signal-based prospecting monitors sponsor activity, including buying signals like funding rounds, phase transitions, enrollment delays, and leadership changes, to identify when sponsors are actively making site selection decisions. The most effective teams combine both approaches: predictive analytics for protocol-specific fit and signal intelligence for commercial timing.
How long does it typically take from signal identification to site selection?
The timeline varies by sponsor size and trial complexity, so track it on your own deals: note the date of each signal (such as positive Phase 2 results) and the date the RFP or feasibility request arrived. Teams that engage during the early signal window, before the RFP is published, have significantly higher success rates than those who enter the process reactively.
